Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07096479

Telpegfilgrastim Injection to Reduce the Risk of Neutropenia in Patients With Solid Tumor

Sponsor: Anhui Provincial Hospital

View on ClinicalTrials.gov

Summary

The objective of this real world study is to confirm the efficacy and saftey of Telpegfilgrastim injection for the prevention of chemotherapy-induced Neutropenia in Patients With Malignant solid tumor.

Official title: A Real World Study on the Efficacy and Safety of Telpegfilgrastim Injection for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Solid Tumor

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

OBSERVATIONAL

Enrollment

318

Start Date

2024-08-15

Completion Date

2025-08-15

Last Updated

2025-07-31

Healthy Volunteers

Not specified

Interventions

DRUG

Telpegfilgrastim Injection

Within 48 ± 12 hours after the end of each chemotherapy cycle, a single subcutaneous injection of a fixed dose of 2mg of Telpegfilgrastim is administered. Use once per chemotherapy cycle and enroll in 1-4 cycles based on the patient's actual condition.

Locations (2)

Anhui province hospital

Hefei, Anhui, China

Anhui province hospital

Hefei, Anhui, China